The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TIGER-3: A phase 3, open-label, randomized study of rociletinib vs cytotoxic chemotherapy in patients (pts) with mutant EGFR non-small cell lung cancer (NSCLC) progressing on prior EGFR TKI therapy and doublet chemotherapy.
 
James Chih-Hsin Yang
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; Pfizer; Roche Pharma AG
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Clovis Oncology; Daiichi Sankyo; Lilly; Merck; MSD; Novartis; Pfizer; Roche/Genentech; Takeda (Inst)
Research Funding - Boehringer Ingelheim (Inst)
 
Sanjay Popat
Consulting or Advisory Role - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Lilly (Inst); MSD (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer (I)
 
Panos Georgiou
Employment - Clovis Oncology
 
Emiko Miyamoto
Employment - Clovis Oncology
 
Jeffrey D. Isaacson
Employment - Clovis Oncology
 
Heather A. Wakelee
Honoraria - Biocon; Peregrine Pharmaceuticals
Consulting or Advisory Role - Peregrine Pharmaceuticals
Research Funding - Agennix (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Xcovery (Inst)
Travel, Accommodations, Expenses - Biocon; Peregrine Pharmaceuticals